1. Home
  2. REVB vs NXTT Comparison

REVB vs NXTT Comparison

Compare REVB & NXTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • NXTT
  • Stock Information
  • Founded
  • REVB 2020
  • NXTT 2019
  • Country
  • REVB United States
  • NXTT China
  • Employees
  • REVB N/A
  • NXTT N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • NXTT
  • Sector
  • REVB Health Care
  • NXTT
  • Exchange
  • REVB Nasdaq
  • NXTT NYSE
  • Market Cap
  • REVB 2.2M
  • NXTT 1.9M
  • IPO Year
  • REVB N/A
  • NXTT N/A
  • Fundamental
  • Price
  • REVB $0.86
  • NXTT $1.36
  • Analyst Decision
  • REVB
  • NXTT
  • Analyst Count
  • REVB 0
  • NXTT 0
  • Target Price
  • REVB N/A
  • NXTT N/A
  • AVG Volume (30 Days)
  • REVB 2.8M
  • NXTT 16.9M
  • Earning Date
  • REVB 05-08-2025
  • NXTT 05-09-2025
  • Dividend Yield
  • REVB N/A
  • NXTT N/A
  • EPS Growth
  • REVB N/A
  • NXTT 21.23
  • EPS
  • REVB N/A
  • NXTT 6.62
  • Revenue
  • REVB N/A
  • NXTT $1,800,000.00
  • Revenue This Year
  • REVB N/A
  • NXTT N/A
  • Revenue Next Year
  • REVB N/A
  • NXTT N/A
  • P/E Ratio
  • REVB N/A
  • NXTT $0.21
  • Revenue Growth
  • REVB N/A
  • NXTT N/A
  • 52 Week Low
  • REVB $0.77
  • NXTT $0.22
  • 52 Week High
  • REVB $60.80
  • NXTT $6.00
  • Technical
  • Relative Strength Index (RSI)
  • REVB 20.22
  • NXTT 45.21
  • Support Level
  • REVB $0.78
  • NXTT $1.50
  • Resistance Level
  • REVB $1.15
  • NXTT $2.89
  • Average True Range (ATR)
  • REVB 0.23
  • NXTT 0.33
  • MACD
  • REVB -0.15
  • NXTT -0.14
  • Stochastic Oscillator
  • REVB 3.38
  • NXTT 6.14

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About NXTT NEXT TECHNOLOGY HOLDING INC

Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.

Share on Social Networks: